תבנית:תרופה/אגרנוקס - Aggrenox

× ×ª×× × ×ª×¨××¤×

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)	B01AC Platelet aggregation inhibitors excluding heparin
××¨××× ×¤×¢×× (ATC5)	*Acetylsalicylic acid 25MG Acetylsalicylic acid 25MG Dipyridamole 200MG Platelet aggregation inhibitors, excl. heparin B01AC Platelet aggregation inhibitors, excl. heparin B01AC 9006968012520 ×× Birkendorfer st.65, 88397 BIBERACH AN DER RISS, GERMANY Acetylsalicylic acid 25MG Dipyridamole 200MG
×¦××¨×ª ××ª×	PER OS
×¦××¨×ª ××× ××	CAPSULES CONTROLLED RELEASE
××ª××××	Secondary prevention of ischaemic strokes and transient ischaemic attacks (TIA).
×ª×× ××ª:× ×ª×× × ×¡×/×ª×¨××¤×/×××¨× ××§×¡ - Aggrenox
××ª×××ª ××× ××	Posology and method of administration
××ª×××××ª × ××	Contraindications
×ª××¤×¢××ª ×××××	Undesirable effects
×ª×××××ª ××× ×ª×¨××¤×ª×××ª	Interaction with other medicinal products and other forms of interaction
×©××××© ××××¨××× ××× ×§×	Pregnancy and Lactation
×¤×¨××§×××× ×××§×	Pharmacodynamic Properties
×¤×¨××§××§×× ×××§×	Pharmacokinetic Properties
×¢××× ××¨××¤× ×××××¨××ª ××¢×××	×¢××× ××¨××¤× ××××¨× ××¢×××

×¢××× ××¦×¨××	*×¢××× ××¦×¨×× ×¢××× ××¦×¨×× ×¢××× ××¦×¨××

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×××¨× ××§×¡ Â® ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	-
××××¢ ××¨×©×ª	-
×©× ××¦×¨×	BOEHRINGER INGELHEIM PHARMA GmbH &CO.KG
×©× ××¢× ××¨××©××	BOEHRINGER INGELHEIM ISRAEL LTD.
×¨××©×××	×ª××¨×× ×××©×: 12/2007. ×¨××©××× ××ª××¨××: 03/2014
×ª××¨×× ×¢×××× ×××¨××	14/05/18

××£ ×× × ××¦×¨ ×¢× ××× ××× ××××××¨ ×ª×× ××ª ×¢× ×¤×¨×× ××ª×¨××¤×.

{{×ª×¨××¤×/×××¨× ××§×¡ - Aggrenox}}

×:

{{×ª×¨××¤×/×××¨× ××§×¡ - Aggrenox
| ×©× ××¤×¨×××¨=×¢×¨× ×××© (×××¨×¡ ××ª ××¢×¨× ×©×××× ×××××¨)
}}

השינוי האחרון נעשה בֹ־14 במאי 2018 ב־13:20

ויקיתרופות